GB201518456D0 - Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases - Google Patents

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases

Info

Publication number
GB201518456D0
GB201518456D0 GBGB1518456.7A GB201518456A GB201518456D0 GB 201518456 D0 GB201518456 D0 GB 201518456D0 GB 201518456 A GB201518456 A GB 201518456A GB 201518456 D0 GB201518456 D0 GB 201518456D0
Authority
GB
United Kingdom
Prior art keywords
autoimmune
inflammatory
treatment
pharmaceutical compositions
novel compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1518456.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Priority to GBGB1518456.7A priority Critical patent/GB201518456D0/en
Publication of GB201518456D0 publication Critical patent/GB201518456D0/en
Priority to BR112018007392A priority patent/BR112018007392A2/pt
Priority to CN201680060910.6A priority patent/CN108137584A/zh
Priority to RU2018117499A priority patent/RU2018117499A/ru
Priority to AU2016343225A priority patent/AU2016343225A1/en
Priority to MX2018004517A priority patent/MX2018004517A/es
Priority to SG11201803095UA priority patent/SG11201803095UA/en
Priority to PCT/EP2016/074662 priority patent/WO2017067848A1/en
Priority to US15/769,260 priority patent/US10508111B2/en
Priority to EP16794525.2A priority patent/EP3365341B1/en
Priority to CA3002255A priority patent/CA3002255A1/en
Priority to JP2018538935A priority patent/JP2018530617A/ja
Priority to KR1020187013738A priority patent/KR20180064528A/ko
Priority to ARP160103166A priority patent/AR106384A1/es
Priority to TW105133608A priority patent/TW201718582A/zh
Priority to IL258707A priority patent/IL258707A/en
Priority to PH12018500827A priority patent/PH12018500827A1/en
Priority to CONC2018/0004765A priority patent/CO2018004765A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1518456.7A 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases Ceased GB201518456D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1518456.7A GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
KR1020187013738A KR20180064528A (ko) 2015-10-19 2016-10-14 6-[5-아미노-6-(2-에톡시에톡시)-이미다조[4,5-비]피리딘-3-일]-니코티노니트릴 유도체 및 아이알에이케이 억제제로서 그의 용도
US15/769,260 US10508111B2 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-B]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK inhibitors
CA3002255A CA3002255A1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
RU2018117499A RU2018117499A (ru) 2015-10-19 2016-10-14 Производные 6-[5-амино-6-(2-этоксиэтокси)-имидазо[4,5-b]пиридин-3-ил]никотинонитрила и их применение в качестве irak ингибиторов
AU2016343225A AU2016343225A1 (en) 2015-10-19 2016-10-14 6-(5-amino-6-(2-ethoxyethoxy)-imidazo(4,5-b)pyridin-3-yl)-nicotinonitrile derivatives and their use as IRAK inhibitors
MX2018004517A MX2018004517A (es) 2015-10-19 2016-10-14 Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).
SG11201803095UA SG11201803095UA (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
PCT/EP2016/074662 WO2017067848A1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
BR112018007392A BR112018007392A2 (pt) 2015-10-19 2016-10-14 derivados de 6-[5-amino-6-(2-etoxietóxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrila e seu uso como inibidores de irak
EP16794525.2A EP3365341B1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
CN201680060910.6A CN108137584A (zh) 2015-10-19 2016-10-14 作为irak抑制剂的6-[5-氨基-6-(2-乙氧基乙氧基)-咪唑并[4,5-b]吡啶-3-基]-烟腈衍生物及其用途
JP2018538935A JP2018530617A (ja) 2015-10-19 2016-10-14 ＩＲＡＫ阻害剤としての６−［５−アミノ−６−（２−エトキシエトキシ）−イミダゾ［４，５−ｂ］ピリジン−３−イル］−ニコチノニトリル誘導体及びその使用
ARP160103166A AR106384A1 (es) 2015-10-19 2016-10-17 Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrilo como inhibidores irak
TW105133608A TW201718582A (zh) 2015-10-19 2016-10-18 用於發炎、自體免疫及/或增生性疾病之治療之新穎化合物及其醫藥組合物
IL258707A IL258707A (en) 2015-10-19 2018-04-15 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
PH12018500827A PH12018500827A1 (en) 2015-10-19 2018-04-17 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
CONC2018/0004765A CO2018004765A2 (es) 2015-10-19 2018-05-03 Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1518456.7A GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases

Publications (1)

Publication Number Publication Date
GB201518456D0 true GB201518456D0 (en) 2015-12-02

Family

ID=55131239

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1518456.7A Ceased GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases

Country Status (18)

Country Link
US (1) US10508111B2 (enExample)
EP (1) EP3365341B1 (enExample)
JP (1) JP2018530617A (enExample)
KR (1) KR20180064528A (enExample)
CN (1) CN108137584A (enExample)
AR (1) AR106384A1 (enExample)
AU (1) AU2016343225A1 (enExample)
BR (1) BR112018007392A2 (enExample)
CA (1) CA3002255A1 (enExample)
CO (1) CO2018004765A2 (enExample)
GB (1) GB201518456D0 (enExample)
IL (1) IL258707A (enExample)
MX (1) MX2018004517A (enExample)
PH (1) PH12018500827A1 (enExample)
RU (1) RU2018117499A (enExample)
SG (1) SG11201803095UA (enExample)
TW (1) TW201718582A (enExample)
WO (1) WO2017067848A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
GB201702603D0 (en) * 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28506A1 (es) * 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
ES2389203T3 (es) * 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
CN103476767B (zh) * 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物
BR112016006319A2 (pt) * 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
UY35935A (es) * 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4

Also Published As

Publication number Publication date
BR112018007392A2 (pt) 2018-10-16
US10508111B2 (en) 2019-12-17
TW201718582A (zh) 2017-06-01
MX2018004517A (es) 2018-06-27
RU2018117499A (ru) 2019-11-21
SG11201803095UA (en) 2018-05-30
WO2017067848A1 (en) 2017-04-27
EP3365341B1 (en) 2020-05-13
IL258707A (en) 2018-06-28
US20180305351A1 (en) 2018-10-25
PH12018500827A1 (en) 2018-10-29
CA3002255A1 (en) 2017-04-27
CN108137584A (zh) 2018-06-08
CO2018004765A2 (es) 2018-07-19
RU2018117499A3 (enExample) 2020-01-24
AU2016343225A1 (en) 2018-05-10
KR20180064528A (ko) 2018-06-14
JP2018530617A (ja) 2018-10-18
AR106384A1 (es) 2018-01-10
EP3365341A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3256438A4 (en) Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
IL256919A (en) Pharmaceutical compositions useful for the treatment of tissue damage
IL252774A0 (en) A pharmaceutical preparation for the treatment of fungus
PL3377075T3 (pl) Kompozycja do leczenia nieswoistego zapalenia jelit
EP3253379A4 (en) Pharmaceutical composition for the treatment of obesity
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)